| Jul 25 |
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
|
| Jul 24 |
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
|
| Jul 24 |
Sage Therapeutics Collapses 19% After Biogen-Tied Essential Tremor Drug Fails
|
| Jul 24 |
Sage Therapeutics Stock Slides as Pipeline Thins
|
| Jul 24 |
Is Biogen (BIIB) an Underappreciated Stock?
|
| Jul 24 |
Biogen, Sage tremor drug fails key trial
|
| Jul 24 |
Biogen, Sage discontinue neuro candidate after mid-stage setback
|
| Jul 24 |
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
|
| Jul 23 |
Nanotechnology in medicine: Who are the leading public companies?
|
| Jul 22 |
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
|
